NeoGenomics Inc (NEO)

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior NotesJune 17, 2026 6:00 AM
Business Wire NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate principal amount of 0.75% convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $41.25 million aggregate principal amount of the notes. The offering is expected to close on June 22, 2026, subject to customary closing conditions. The notes will be senior, unsecured obligations of NeoGenomics and will bear interest at a rate of 0.75% per year payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2027. The notes will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. Before April 1, 2032, noteholders will have the right to convert their notes in certain circumstances and during specified periods. From and after April 1, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. NeoGenomics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.001 per share (“common stock”), or a combination of cash and shares of its common stock, at NeoGenomics’ election. The initial conversion rate is 70.6140 shares of common stock per $1,000 principal amount of the notes, which represents an initial conversion price of approximately $14.16 per share of NeoGenomics’ common stock. The initial conversion price represents a premium of approximately 35% to the last reported sale price of $10.49 per share of the common stock on The Nasdaq Capital Market on June 16, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at NeoGenomics’ option at any time, and from time to time, on or after July 6, 2029 and on or before the 51st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of NeoGenomics’ common stock equals or exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, the notes will be redeemable at any time if the aggregate principal amount of the notes that remains outstanding is less than 15% of the aggregate principal amount of the notes initially issued in the offering and certain other conditions are satisfied. In connection with the pricing of the notes, NeoGenomics entered into privately negotiated capped call transactions with certain financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to NeoGenomics’ common stock upon conversion of any notes and/or offset any potential cash payments NeoGenomics is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions will initially be $20.98 per share of NeoGenomics’ common stock, which represents a premium of 100% to the last reported sale price of $10.49 per share of the common stock on The Nasdaq Capital Market on June 16, 2026. NeoGenomics has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of NeoGenomics’ common stock and/or enter into various derivative transactions with respect to NeoGenomics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock or the notes at that time. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to NeoGenomics’ common stock and/or purchasing or selling NeoGenomics’ common stock or other securities of NeoGenomics in secondary market transactions from time to time prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes or following certain repurchases or redemptions of the notes). This activity could cause or avoid an increase or a decrease in the market price of NeoGenomics’ common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of such notes. NeoGenomics estimates that the net proceeds from the offering of the notes will be approximately $266.15 million (or approximately $306.16 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by NeoGenomics. NeoGenomics intends to use approximately $25 million of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, NeoGenomics expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, NeoGenomics intends to use a portion of the net proceeds from the offering, together with cash on hand, to repurchase for cash $276 million aggregate principal amount of NeoGenomics’ 0.25% convertible senior notes due 2028 (the “existing notes”) through privately negotiated transactions entered into concurrently with the pricing of the notes effected through one or more of the initial purchasers or their affiliates as our agents, and the remaining net proceeds from the offering, if any, together with cash on hand, to repurchase up to an aggregate of $25 million of our outstanding shares of common stock from certain purchasers of notes in privately negotiated transactions, effected through one or more of the initial purchasers or their respective affiliates as our agent, entered into concurrently with the closing of this offering, and the remainder of the net proceeds, if any, for general corporate purposes. The concurrent repurchases of the existing notes and shares of the Company’s common stock described above may result in the Company’s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes to be offered. Concurrently with the pricing of the notes, NeoGenomics entered into privately negotiated transactions (the “note repurchase transactions”) with certain holders of the existing notes to repurchase for cash $276 million aggregate principal amount of the existing notes for a total repurchase cost (including accrued and unpaid interest) of approximately $263.19 million. The terms of the note repurchase transactions were individually negotiated with certain holders of the existing notes and depended on a variety of factors, including the market price of NeoGenomics’ common stock and the trading price of the existing notes. This press release is not an offer to repurchase the existing notes, and the offering of the notes is not contingent upon the repurchase of the existing notes. In connection with the note repurchase transactions, NeoGenomics expects that holders of the existing notes who have agreed to have their existing notes repurchased and who have hedged their equity price risk with respect to such existing notes (the “hedged holders”) will unwind all or part of their hedge positions by buying NeoGenomics’ common stock and/or entering into or unwinding various derivative transactions with respect to NeoGenomics’ common stock. The amount of NeoGenomics’ common stock to be purchased by the hedged holders or the notional number of shares of NeoGenomics’ common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of NeoGenomics’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. NeoGenomics cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or NeoGenomics’ common stock and the corresponding effect on the initial conversion price of the notes. The notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements, which include those concerning whether NeoGenomics will issue the notes; whether the note repurchase transactions will settle; whether the common stock repurchase transactions will settle; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the hedged holders, the option counterparties and their respective affiliates; and whether the capped call transactions will become effective, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks with respect to the market acceptance of the Company’s products and services, as well as the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission (SEC). We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260617584382/en/ Investor Contact
InvestorRelations@neogenomics.com Media Contact
Andrea Sampson
asampson@sampsonprgroup.com Original: NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior NotesJune 15, 2026 5:24 PM
Business Wire NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $41.25 million aggregate principal amount of the notes. The offering of the notes is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The notes will be senior, unsecured obligations of NeoGenomics, will accrue interest payable semi-annually in arrears and will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. NeoGenomics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.001 per share (“common stock”), or a combination of cash and shares of its common stock, at NeoGenomics’ election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at NeoGenomics’ option at any time, and from time to time, on or after July 6, 2029 and on or before the 51st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of NeoGenomics’ common stock equals or exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, the notes will be redeemable at any time if the aggregate principal amount of the notes that remains outstanding is less than 15% of the aggregate principal amount of the notes initially issued in the offering and certain other conditions are satisfied. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. In connection with the pricing of the notes, NeoGenomics expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates or other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to NeoGenomics’ common stock upon conversion of any notes and/or offset any potential cash payments NeoGenomics is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. NeoGenomics has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of NeoGenomics’ common stock and/or enter into various derivative transactions with respect to NeoGenomics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock or the notes at that time. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to NeoGenomics’ common stock and/or purchasing or selling NeoGenomics’ common stock or other securities of NeoGenomics in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes or following certain repurchases or redemptions of the notes). This activity could cause or avoid an increase or a decrease in the market price of NeoGenomics’ common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of such notes. NeoGenomics intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, NeoGenomics expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, NeoGenomics intends to use a portion of the remaining net proceeds from the offering, together with cash on hand, to repurchase a portion of NeoGenomics’ 0.25% convertible senior notes due 2028 (the “existing notes”) through privately negotiated transactions entered into concurrently with the pricing of the notes effected through one or more of the initial purchasers or their affiliates as our agents, and a portion of the remaining net proceeds from the offering, if any, together with cash on hand, to repurchase up to $25 million of shares of our outstanding common stock from certain purchasers of the notes in privately negotiated transactions, effected through one or more of the initial purchasers or their respective affiliates as our agent, entered into concurrently with the pricing of this offering, and the remainder of the net proceeds, if any, for general corporate purposes. The concurrent repurchases of the existing notes and shares of Company’s common stock described above may result in the Company’s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes to be offered. NeoGenomics expects to repurchase for cash a portion of the existing notes through privately negotiated transactions (the “note repurchase transactions”) entered into concurrently with the pricing of the notes. The terms of each note repurchase transaction will depend on a variety of factors, including the market price of NeoGenomics’ common stock and the trading price of the existing notes at the time of the note repurchase transactions. No assurance can be given as to how much, if any, of the existing notes will be repurchased or the terms on which they will be repurchased. This press release is not an offer to repurchase the existing notes, and the offering of the notes is not contingent upon the repurchase of the existing notes. In connection with the note repurchase transactions, NeoGenomics expects that holders of the existing notes who agree to have their existing notes repurchased and who have hedged their equity price risk with respect to such existing notes (the “hedged holders”) will unwind all or part of their hedge positions by buying NeoGenomics’ common stock and/or entering into or unwinding various derivative transactions with respect to NeoGenomics’ common stock. The amount of NeoGenomics’ common stock to be purchased by the hedged holders or the notional number of shares of NeoGenomics’ common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of NeoGenomics’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. NeoGenomics cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or NeoGenomics’ common stock and the corresponding effect on the initial conversion price of the notes. The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements, which include those concerning NeoGenomics’ future expectations, plans and prospects, including, without limitation, statements regarding: whether NeoGenomics will offer and issue the notes and the terms of the notes; whether NeoGenomics will repurchase any existing notes or shares of outstanding common stock and the terms of any repurchase transactions; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the hedged holders, the option counterparties and their respective affiliates; and whether the capped call transactions will become effective and the terms of the capped call transactions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks with respect to the market acceptance of the Company’s products and services, as well as the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission (SEC). We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260615452524/en/ Investor Contact
InvestorRelations@neogenomics.com Media Contact
Andrea Sampson
asampson@sampsonprgroup.com Original: NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

NeoGenomics to Present New Research at ASCO Annual Meeting 2026May 26, 2026 7:05 AM
Business Wire Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130). The abstracts demonstrate NeoGenomics' expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD). These findings include an online presentation on the utilization of RaDaR® ST in a colorectal cancer cohort, as reflected in an interim analysis from a collaboration with investigators at MD Anderson Cancer Center. To support biopharma partners advancing ADCs, BiTES, bispecifics, radioligands, and targeted therapies, NeoGenomics will highlight new biomarkers, including B7-H3, CD137, EZH2, and PRMT5. The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited. NeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient. Both will be reflected throughout the booth, alongside the company's new tagline, 'Answers are in our DNA.' “A cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from first diagnosis through recurrence monitoring,” said Tony Zook, CEO of NeoGenomics. “The breadth of our ASCO research and a sharpened mission reflect our commitment to providing personalized answers for every cancer patient." Presentations and online abstracts at ASCO include: Poster #177: Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing Session: Quality Care/Health Services Research Monday, June 1, 9 AM to 12 PM CDT | Hall A Poster #337: From Infancy to Young Adulthood: Exploring the divergent genomic mechanisms that drive AML Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Monday, June 1, 9 AM to 12 PM CDT | Hall A Poster #129a: Interception of Molecular Relapse in Breast Cancer: The SURVIVE HERoes Study (NCT06643585) Session: Breast Cancer—Local/Regional/Adjuvant Monday, June 1, 1:30 to 4:30 PM CDT | Hall A Poster #135a: The SURVIVE Study: Re-evaluating Follow-up in Early Breast Cancer Session: Breast Cancer—Local/Regional/Adjuvant Monday, June 1, 1:30 to 4:30 PM CDT | Hall A Online Abstract: Concordance of liquid biopsy and tissue CGP for identification of guideline-recommended actionable variants Online Abstract: Real-world evidence for comprehensive genomic profiling in myeloid malignancies: changes in detection and clinical impact Online Abstract: Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center Online Abstract: Clinical actionability and molecular landscapes of fusion-driven sarcomas: A multi-modal integration analysis of comprehensive genomic profiling, targeted RNA-sequencing, and PD-L1 expression About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the Company’s strategy, planned future operations and development plans and initiatives, as well as the timing, outcome and potential for its offerings to deliver higher sensitivity results with faster turnaround times compared to currently available assays, and the potential impact on clinical treatment and patient prognosis. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to successfully complete development of and to offer new types of tests, to execute on its strategic priorities and to otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260526677942/en/ Media Contact
Andrea Sampson
asampson@sampsonprgroup.com Investor Contact
InvestorRelations@neogenomics.com Original: NeoGenomics to Present New Research at ASCO Annual Meeting 2026

NeoGenomics to Participate in Upcoming Investor ConferencesMay 15, 2026 9:05 AM
Business Wire NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis
Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York
Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A webcast of the Jefferies fireside chat can be accessed here, and an archived replay will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515415608/en/ Investor Contact
InvestorRelations@neogenomics.com Media Contact
Andrea Sampson
asampson@sampsonprgroup.com Original: NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics Shares Jump on Earnings and Analyst UpgradesApril 29, 2026 7:27 AM
IH Market News
NeoGenomics Inc. (NASDAQ:NEO) shares climbed 7.43% after the company reported quarterly results and received multiple analyst upgrades, including a rating boost from Leerink Partners.Leerink upgraded the stock to Outperform from Market Perform and raised its price target to $25 from $12.“We are upgrading NEO to Outperform from Market Perform. The company delivers on its one-stop shop business model in oncology diagnostics and is getting back on track, in our view – with strong momentum, profitability, and attractive valuation that cannot be ignored. We are raising our price target to $25 at 3.4x EV/Sales (vs. $12, 1.5x before).”NeoGenomics reported first-quarter 2026 revenue of $187 million, up 11% year over year and above analyst expectations of $184.53 million. Adjusted EBITDA increased 27% to $9 million.Earnings per share came in at $0.01, in line with forecasts. Growth was driven by strong demand for next-generation sequencing and clinical testing services.Analysts at Benchmark Company also upgraded the stock to Buy, describing the first-quarter performance as solid.NeoGenomics stock price

Original: NeoGenomics Shares Jump on Earnings and Analyst Upgrades

NeoGenomics Reports First Quarter 2026 ResultsApril 28, 2026 4:05 PM
Business Wire
First quarter total revenue increased 11% YoY to $187 million;


Clinical revenue grew 14%, including NGS growth of 26%;


Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million


NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March 31, 2026.




First Quarter 2026 Financial Highlights As Compared To First Quarter 2025








 









Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%








 









Net loss decreased 34% to $17 million








 









Adjusted EBITDA(1) was positive $9 million, an increase of 27% from prior year








 









First Quarter 2026 Operating Highlights








 









Launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), which we estimate represents a $20 billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated.








 









Announced a favorable MolDX coverage decision for PanTracer™ LBx, its blood-based comprehensive genomic profiling (CGP) test designed to support therapy selection and clinical trial enrollment in patients with advanced solid tumors.








 









Introduced PanTracer Pro, a new addition to the PanTracer® Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.








 







“The first quarter of 2026 was a truly transformational one for NeoGenomics. We again delivered double-digit revenue growth while making meaningful strides in our efforts to bring the latest innovation in advanced cancer testing to the community setting,” stated Tony Zook, Chief Executive Officer of NeoGenomics. “The full clinical launch of our RaDaR® ST MRD assay in February represents an important advancement in residual disease monitoring, which we estimate represents a $20 billion addressable market that is underpenetrated and growing rapidly. Additionally, we believe the receipt of MolDX reimbursement coverage for PanTracer LBx and the launch of PanTracer Pro addresses a significant need among our customers and complements our PanTracer Tissue offering, which has seen robust growth in test volumes over the past two years. These important additions further differentiate our portfolio, advancing our objective to deliver long-term predictable revenue growth while helping community providers achieve optimal outcomes for their patients.”


First-Quarter Results


Consolidated revenue for the first quarter of 2026 was $187 million, an increase of 11% over the same period in 2025. Average revenue per clinical test increased by 8% to $495 with 9% growth excluding recently acquired Pathline tests.


Consolidated gross profit for the first quarter of 2026 was $81 million, an increase of 10% compared to the first quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 43%. Adjusted Gross Profit Margin(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 46%.


Operating expenses for the first quarter of 2026 were $99 million, a decrease of $2 million, or 2%, compared to the first quarter of 2025.


Net loss for the quarter decreased by $9 million, or 34%, to $17 million compared to net loss of $26 million for the first quarter of 2025.


Adjusted EBITDA(1) for the first quarter of 2026 increased by 27% to $9.0 million, compared to $7.1 million in the first quarter of 2025. Adjusted Net Income(1) was $1.4 million compared to Adjusted Net Loss(1) of $0.5 million in the first quarter of 2025.


Cash and cash equivalents and marketable securities totaled $146 million at quarter end.




(1)







The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.







2026 Financial Guidance


The Company revised its full-year 2026 guidance, as initially issued on February 17, 2026 (in millions).




 






 






FY 2025






 






Initial




FY 2026

Guidance






 






Revised




FY 2026

Guidance






 






YOY % Change from FY

2025








(in millions)






 






Actual






 






Low






 






High






 






Low






 






High






 






Low






 






High








Consolidated revenue






 






$727






 






$793






 






$801






 






$797






 






$803






 






10%






 






10%








Net loss






 






$(108)






 






$(63)






 






$(50)






 






$(63)






 






$(50)






 






42%






 






54%








Adjusted EBITDA






 






$43






 






$55






 






$57






 






$55






 






$57






 






27%






 






31%







Conference Call


The Company has scheduled a webcast and conference call to discuss its first quarter 2026 results on Tuesday, April 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 750346. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.


About NeoGenomics, Inc.


NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.


We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).


Forward Looking Statements


This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “enable,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include statements regarding the Company’s strategy, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, and estimates of market size and position, as well as statements regarding the design and expected capabilities of the Company's test offerings and the objectives of management. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities, to enter new markets and increase market share in both current and new markets, to assemble and maintain an effective executive team, to continue gaining new customers, develop and commercialize new types of tests, integrate its acquisitions, manage the effects of seasonality, execute on its long-range strategic priorities and otherwise implement its business plans, as well as the potential impact of evolving regulatory requirements related to laboratory developed tests, the impact of tariffs and trade policy uncertainty on the Company's supply chain and costs, and any potential reimbursement changes by the government and commercial payors, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and filed with the SEC on February 17, 2026, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the SEC.


We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.




NeoGenomics, Inc.




CONDENSED CONSOLIDATED BALANCE SHEETS




(in thousands)











 



 






 






March 31, 2026

(unaudited)






 






December 31, 2025








ASSETS






 






 






 






 








Current assets






 






 






 






 








Cash and cash equivalents






 






$






146,143






 






$






159,618








Accounts receivable, net






 






 






167,424






 






 






159,242








Inventories






 






 






29,837






 






 






28,566








Prepaid assets






 






 






23,666






 






 






21,443








Other current assets






 






 






6,614






 






 






7,417








Total current assets






 






 






373,684






 






 






376,286








Property and equipment, net






 






 






83,659






 






 






84,834








Operating lease right-of-use assets






 






 






76,703






 






 






78,444








Intangible assets, net






 






 






278,895






 






 






286,528








Goodwill






 






 






523,995






 






 






524,344








Other assets






 






 






9,595






 






 






9,394








Total non-current assets






 






 






972,847






 






 






983,544








Total assets






 






$






1,346,531






 






$






1,359,830








 






 






 






 






 








LIABILITIES AND STOCKHOLDERS’ EQUITY






 






 






 






 








Current liabilities






 






 






 






 








Accounts payable and other current liabilities






 






$






79,762






 






$






83,524








Current portion of operating lease liabilities






 






 






4,828






 






 






4,776








Total current liabilities






 






 






84,590






 






 






88,300








Long-term liabilities






 






 






 






 








Operating lease liabilities






 






 






61,461






 






 






62,822








Convertible senior notes, net






 






 






342,240






 






 






341,858








Deferred income tax liabilities, net






 






 






17,450






 






 






18,219








Other long-term liabilities






 






 






12,030






 






 






12,069








Total long-term liabilities






 






 






433,181






 






 






434,968








Total liabilities






 






$






517,771






 






$






523,268








Stockholders’ equity






 






 






 






 








Total stockholders' equity






 






$






828,760






 






$






836,562








Total liabilities and stockholders’ equity






 






$






1,346,531






 






$






1,359,830









NeoGenomics, Inc.




CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS




(in thousands, except per share amounts)




(unaudited)









 



 






 






Three Months Ended March 31,








 






 






2026






 






2025








NET REVENUE






 






$






186,672






 






 






$






168,035






 








 






 






 






 






 








COST OF REVENUE






 






 






105,808






 






 






 






94,789






 








 






 






 






 






 








GROSS PROFIT






 






 






80,864






 






 






 






73,246






 








Operating expenses:






 






 






 






 








General and administrative






 






 






65,741






 






 






 






68,207






 








Research and development






 






 






9,534






 






 






 






10,181






 








Sales and marketing






 






 






23,830






 






 






 






22,683






 








Total operating expenses






 






 






99,105






 






 






 






101,071






 








LOSS FROM OPERATIONS






 






 






(18,241






)






 






 






(27,825






)








Interest income






 






 






(1,273






)






 






 






(3,721






)








Interest expense






 






 






598






 






 






 






1,618






 








Other expense (income), net






 






 






12






 






 






 






(65






)








Loss before taxes






 






 






(17,578






)






 






 






(25,657






)








Income tax (benefit) expense






 






 






(472






)






 






 






266






 








NET LOSS






 






$






(17,106






)






 






$






(25,923






)








 






 






 






 






 








NET LOSS PER SHARE






 






 






 






 








Basic






 






$






(0.13






)






 






$






(0.20






)








Diluted






 






$






(0.13






)






 






$






(0.20






)








 






 






 






 






 








WEIGHTED AVERAGE COMMON SHARES OUTSTANDING






 






 






 






 








Basic






 






 






129,166






 






 






 






127,376






 








Diluted






 






 






129,166






 






 






 






127,376






 









NeoGenomics, Inc.




CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS




(in thousands)




(unaudited)









 



 






 






Three Months Ended March 31,








 






 






2026






 






2025








CASH FLOWS FROM OPERATING ACTIVITIES






 






 






 






 








Net loss






 






$






(17,106






)






 






$






(25,923






)








Adjustments to reconcile net loss to net cash used in operating activities:






 






 






 






 








Depreciation






 






 






8,780






 






 






 






9,366






 








Amortization of intangibles






 






 






7,633






 






 






 






8,362






 








Stock-based compensation






 






 






9,636






 






 






 






10,754






 








Non-cash operating lease expense






 






 






1,720






 






 






 






1,584






 








Other adjustments






 






 






402






 






 






 






772






 








Changes in assets and liabilities, net






 






 






(19,202






)






 






 






(30,242






)








Net cash used in operating activities






 






 






(8,137






)






 






 






(25,327






)








CASH FLOWS FROM INVESTING ACTIVITIES






 






 






 






 








Proceeds from maturities of marketable securities






 






 






—






 






 






 






8,060






 








Purchases of property and equipment






 






 






(5,000






)






 






 






(4,500






)








Net cash (used in) provided by investing activities






 






 






(5,000






)






 






 






3,560






 








CASH FLOWS FROM FINANCING ACTIVITIES






 






 






 






 








Issuance of common stock, net






 






 






(338






)






 






 






949






 








Net cash (used in) provided by financing activities






 






 






(338






)






 






 






949






 








Net change in cash and cash equivalents






 






 






(13,475






)






 






 






(20,818






)








Cash and cash equivalents, beginning of period






 






 






159,618






 






 






 






367,012






 








Cash and cash equivalents, end of period






 






$






146,143






 






 






$






346,194






 







Use of Non-GAAP Financial Measures


The Company reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”). However, in order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company’s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company’s core test-level operating results across reporting periods. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results and may exclude items that are significant to understanding and assessing the Company's financial results. Therefore, these measures should not be considered measures of liquidity or considered in isolation or as an alternative to other measures of the Company's profitability or performance under GAAP. The Company's presentation of non-GAAP financial measures is unlikely to be comparable to similarly-titled non-GAAP financial measures provided by other companies.


Definitions of Non-GAAP Financial Measures


Non-GAAP Adjusted EBITDA


“Adjusted EBITDA” is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income, (ii) interest expense, (iii) income tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) acquisition and integration related expenses, (viii) intellectual property (“IP”) litigation costs, and (ix) other significant or non-operating (income) or expenses, net.


Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin


“Adjusted cost of revenue” is defined by NeoGenomics as cost of revenue before: (i) amortization of acquired intangible assets, and (ii) stock-based compensation expense.


“Adjusted gross profit” is defined by NeoGenomics as total revenue less adjusted cost of revenue.


“Adjusted gross profit margin” is defined by NeoGenomics as adjusted cost of revenue divided by total revenue.


Non-GAAP Adjusted Net (Loss) Income


“Adjusted net (loss) income” is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) acquisition and integration related expenses, (v) IP litigation costs, and (vi) other significant or non-operating (income) or expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method.


Non-GAAP Adjusted Diluted EPS


“Adjusted diluted EPS” is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.


The following tables present reconciliations of the Company's non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP.




Reconciliation of GAAP Net Loss to Non-GAAP EBITDA and Adjusted EBITDA




(in thousands)




(unaudited)









 



 






 






Three Months Ended March 31,








 






 






2026






 






2025








Net loss (GAAP)






 






$






(17,106






)






 






$






(25,923






)








Adjustments to net loss:






 






 






 






 








Interest income






 






 






(1,273






)






 






 






(3,721






)








Interest expense






 






 






598






 






 






 






1,618






 








Income tax (benefit) expense






 






 






(472






)






 






 






266






 








Depreciation






 






 






8,780






 






 






 






9,366






 








Amortization of intangibles






 






 






7,633






 






 






 






8,362






 








EBITDA (non-GAAP)






 






$






(1,840






)






 






$






(10,032






)








Further adjustments to EBITDA:






 






 






 






 








CEO transition costs(1)






 






 






—






 






 






 






2,193






 








Acquisition and integration related expenses(2)






 






 






806






 






 






 






1,172






 








Stock-based compensation expense






 






 






9,636






 






 






 






10,754






 








IP litigation costs(3)






 






 






—






 






 






 






2,983






 








Other significant expenses, net(4)






 






 






402






 






 






 






—






 








Adjusted EBITDA (non-GAAP)






 






$






9,004






 






 






$






7,070






 









_________________








(1)







For the three months ended March 31, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three months ended March 31, 2026.








(2)







For the three months ended March 31, 2026, acquisition and integration related expenses include severance costs. For the three months ended March 31, 2025, acquisition and integration related expenses include legal and consulting costs.








(3)







For the three months ended March 31, 2025, IP litigation costs include legal fees. There were no such costs for the three months ended March 31, 2026.








(4)







For the three months ended March 31, 2026, other significant (income) expenses, net, includes executive retention costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three months ended March 31, 2025.









Reconciliation of Consolidated GAAP Cost of Revenue, Gross Profit and Gross Profit Margin to




Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin




(dollars in thousands)




(unaudited)









 



 






 






Three Months Ended March 31,








 






 






2026






 






2025






 






% Change








Consolidated:






 






 






 






 






 






 








Total revenue (GAAP)






 






$






186,672






 






 






$






168,035






 






 






11.1






%








 






 






 






 






 






 






 








Cost of revenue (GAAP)






 






$






105,808






 






 






$






94,789






 






 






11.6






%








Adjustments to cost of revenue(1)






 






 






(4,951






)






 






 






(5,325






)






 






 








Adjusted cost of revenue (non-GAAP)






 






$






100,857






 






 






$






89,464






 






 






12.7






%








 






 






 






 






 






 






 








Gross profit (GAAP)






 






$






80,864






 






 






$






73,246






 






 






10.4






%








Adjusted gross profit (non-GAAP )






 






$






85,815






 






 






$






78,571






 






 






9.2






%








 






 






 






 






 






 






 








Gross profit margin (GAAP)






 






 






43.3






%






 






 






43.6






%






 






 








Adjusted gross profit margin (non-GAAP)






 






 






46.0






%






 






 






46.8






%






 






 









_______________








(1)







Cost of revenue adjustments for the three months ended March 31, 2026, includes $4.6 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the three months ended March 31, 2025, includes $4.9 million of amortization of acquired intangible assets and $0.4 million of stock-based compensation.









Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss




and GAAP EPS to Non-GAAP Adjusted EPS




(in thousands, except per share amounts)




(unaudited)









 



 






 






Three Months Ended March 31,








 






 






2026






 






2025








Net loss (GAAP)






 






$






(17,106






)






 






$






(25,923






)








Adjustments to net loss, net of tax:






 






 






 






 








Amortization of intangibles






 






 






7,633






 






 






 






8,362






 








CEO transition costs(1)






 






 






—






 






 






 






2,193






 








Acquisition and integration related expenses(2)






 






 






806






 






 






 






1,172






 








Stock-based compensation expense






 






 






9,636






 






 






 






10,754






 








IP litigation costs(3)






 






 






—






 






 






 






2,983






 








Other significant expenses, net(4)






 






 






402






 






 






 






—






 








Adjusted net income/(loss)






 






$






1,371






 






 






$






(459






)








 






 






 






 






 








Net loss per common share (GAAP)






 






 






 






 








Diluted EPS






 






$






(0.13






)






 






$






(0.20






)








Adjustments to diluted loss income per share:






 






 






 






 








Amortization of intangibles






 






 






0.06






 






 






 






0.07






 








CEO transition costs(1)






 






 






—






 






 






 






0.02






 








Acquisition and integration related expenses(2)






 






 






0.01






 






 






 






0.01






 








Stock-based compensation expense






 






 






0.07






 






 






 






0.08






 








IP litigation costs(3)






 






 






—






 






 






 






0.02






 








Other significant expenses, net(4)






 






 






0.01






 






 






 






—






 








Rounding and impact of diluted shares in adjusted diluted shares(5)






 






 






(0.01






)






 






 






—






 








Adjusted diluted EPS (non-GAAP)






 






$






0.01






 






 






$






—






 








 






 






 






 






 








Weighted average shares used in computation of adjusted diluted EPS:






 






 






 






 








Diluted common shares (GAAP)






 






 






129,166






 






 






 






127,376






 








Dilutive effect of options, restricted stock, and converted shares(6)(7)






 






 






—






 






 






 






—






 








Adjusted diluted shares outstanding (non-GAAP)






 






 






129,166






 






 






 






127,376






 









_______________








(1)







For the three months ended March 31, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three months ended March 31, 2026.








(2)







For the three months ended March 31, 2026, acquisition and integration related expenses include severance costs. For the three months ended March 31, 2025, acquisition and integration related expenses include legal and consulting costs.








(3)







For the three months ended March 31, 2025, IP litigation costs include legal fees. There were no such costs for the three months ended March 31, 2026.








(4)







For the three months ended March 31, 2026, other significant (income) expenses, net, includes executive retention costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three months ended March 31, 2025.








(5)







This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive or GAAP net (loss) income is positive and adjusted net (loss) income is negative, also compensates for the effects of additional diluted shares included or excluded in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.








(6)







In those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.








(7)







In those periods in which GAAP net (loss) income is positive and adjusted net (loss) income is negative, this adjustment excludes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.







Reconciliation of Non-GAAP Financial Guidance to Corresponding GAAP Measures

(in thousands, except per share amounts)

(unaudited)


GAAP net loss in 2026 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share.


The following table reconciles the Company’s 2026 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS:




 






 






Year Ended December 31, 2026








 






 






Low Range






 






High Range








Net loss (GAAP)






 






$






(63,000






)






 






$






(50,000






)








Amortization of intangibles






 






 






30,000






 






 






 






30,000






 








Stock-based compensation expenses






 






 






43,000






 






 






 






40,000






 








Other one-time expenses






 






 






11,000






 






 






 






7,000






 








Adjusted net income (non-GAAP)






 






 






21,000






 






 






 






27,000






 








Interest and taxes






 






 






(5,000






)






 






 






(6,000






)








Depreciation






 






 






39,000






 






 






 






36,000






 








Adjusted EBITDA (non-GAAP)






 






$






55,000






 






 






$






57,000






 








 






 






 






 






 








Net loss per diluted share (GAAP)






 






$






(0.48






)






 






$






(0.38






)








Adjustments to net loss per diluted share:






 






 






 






 








Amortization of intangibles






 






 






0.23






 






 






 






0.23






 








Stock-based compensation expenses






 






 






0.33






 






 






 






0.31






 








Other one-time expenses






 






 






0.08






 






 






 






0.05






 








Rounding and impact of diluted shares in adjusted diluted shares(1)






 






 






—






 






 






 






—






 








Adjusted diluted EPS(1) (non-GAAP)






 






$






0.16






 






 






$






0.21






 








 






 






 






 






 








Weighted average assumed shares outstanding in 2026:






 






 






 






 








Diluted shares (GAAP)






 






 






130,000






 






 






 






130,000






 








Options, restricted stock, and converted shares not included in diluted shares(2)






 






 






—






 






 






 






—






 








Adjusted diluted shares outstanding (non-GAAP)






 






 






130,000






 






 






 






130,000






 









_________________








(1)







This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.








(2)







For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.









Supplemental Information




Clinical Tests Performed and Revenue




(unaudited)









 



 






 






Three Months Ended March 31, 2026








 






 






2026






 






2025






 






% Change








Clinical including Pathline(1):






 






 






 






 






 






 








Number of tests performed






 






 






345,679






 






 






326,163






 






6.0






%








Average revenue/test






 






$






495






 






$






459






 






7.8






%








 






 






 






 






 






 






 








Clinical excluding Pathline(2):






 






 






 






 






 






 








Number of tests performed






 






 






335,155






 






 






326,163






 






2.8






%








Average revenue/test






 






$






501






 






$






459






 






9.2






%









_________________








(1)







Excludes tests and revenue related to non-clinical activity.








(2)







Excludes tests and revenue related to Pathline and non-clinical activity.







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428135552/en/
Investor Contact

InvestorRelations@neogenomics.com


Media Contact

Andrea Sampson

asampson@sampsonprgroup.com


Original: NeoGenomics Reports First Quarter 2026 Results